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Am J Physiol Heart Circ Physiol 303: H323–H331, 2012. First
published May 25, 2012; doi:10.1152/ajpheart.00749.2011.—Cardiac
myosin-binding protein C (cMyBP-C) is involved in the regulation of
cardiac myofilament contraction. Recent evidence showed that protein
kinase D (PKD) is one of the kinases that phosphorylate cMyBP-C.
However, the mechanism by which PKD-induced cMyBP-C phos-
phorylation affects cardiac contractile responses is not known. Using
immunoprecipitation, we showed that, in contracting cardiomyocytes,
PKD binds to cMyBP-C and phosphorylates it at Ser315. The effect of
PKD-mediated phosphorylation of cMyBP-C on cardiac myofilament
function was investigated in permeabilized ventricular myocytes,
isolated from wild-type (WT) and from cMyBP-C knockout (KO)
mice, incubated in the presence of full-length active PKD. In WT
myocytes, PKD increased both myofilament Ca2 sensitivity (pCa50)
and maximal Ca2-activated tension of contraction (Tmax). In
cMyBP-C KO skinned myocytes, PKD increased pCa50 but did not
alter Tmax. This suggests that cMyBP-C is not involved in PKD-
mediated sensitization of myofilaments to Ca2 but is essential for
PKD-induced increase in Tmax. Furthermore, the phosphorylation of
both PKD-Ser916 and cMyBP-C-Ser315 was contraction frequency-
dependent, suggesting that PKD-mediated cMyBP-C phosphorylation
is operational primarily during periods of increased contractile activ-
ity. Thus, during high contraction frequency, PKD facilitates contrac-
tion of cardiomyocytes by increasing Ca2 sensitivity and by an
increased Tmax through phosphorylation of cMyBP-C.
cardiomyocyte contractility; calcium sensitivity; protein kinase A;
phospho-cardiac myosin-binding protein C-serine-315
PROTEIN KINASE D (PKD) belongs to a serine/threonine kinase
family that is closely related to novel and conventional mem-
bers of the protein kinase C (PKC) family, with which it shares
the ability to be activated by diacylglycerol (DAG) (26). One
of the mechanisms to activate PKD is via an A-kinase anchor-
ing protein, AKAP-Lbc, which assembles a PKD activation
complex and targets PKD to a specific subcellular location (3).
AKAP-Lbc then recruits an upstream kinase, PKC, and coor-
dinates protein kinase A (PKA) phosphorylation events that
lead to the release of activated PKD at a specific location into
the cell. Thus, AKAP-Lbc synchronizes PKA and PKC activ-
ities in a manner that leads to the activation of PKD (3).
Several proteins have been identified to be substrates of
PKD, including cardiac troponin I (TnI), telethonin, and car-
diac myosin-binding protein C (cMyBP-C) (9). cMyBP-C is a
component of the cardiac sarcomere thick filaments that con-
tributes to myosin assembly (1). cMyBP-C prevents weakly
bound cross-bridges and increases force during the power
stroke, thereby limiting ATP consumption per cross-bridge
force production cycle (25). Furthermore, cMyBP-C has been
shown to play a role in maintaining complete relaxation of
cardiomyocytes (34). Several animal models have been devel-
oped to evaluate the role of cMyBP-C. Most of the introduced
mutations in the cMyBP-C gene resulted in hypertrophic car-
diomyopathy, indicative for a reduced contractile power (43).
In rat, three phosphorylation sites have been identified in the
MyBP-C motif located between C1 and C2, including Ser286,
Ser295, and Ser315 (45, 46). In mouse myocardium, the cMyBP-
C-Ser302 is structurally identical to the Ser315 phosphorylation
site in rat. Upon phosphorylation of the MyBP-C motif,
cMyBP-C interacts with the S2 region of myosin at its C1-C2-
MyBP-C domains (1). cMyBP-C also binds to actin at the
C1-MyBP-C motif, which could be important for the arrange-
ment of myosin-actin filaments in the sarcomere (1). Phosphor-
ylation of cMyBP-C by PKA appears to accelerate the rates of
force development in systole and the rates of relaxation in
diastole, thereby increasing cardiac contractility (8, 10). Re-
cently, in connection with an observed binding of PKD to
cMyBP-C in quiescent trabeculae, Bardswell and coworkers
(1) demonstrated that the catalytic subunit of PKD interacts
with cMyBP-C-Ser302 in skinned mouse myocardium. Inde-
pendently, PKD has been shown to be activated during con-
traction of cardiomyocytes (12, 28). Whether PKD-mediated
cMyBP-C phosphorylation is also increased upon contraction
of cardiomyocytes remains to be established.
Phosphorylation of cMyBP-C is significantly reduced in
patients with heart failure as it is in experimental models
mimicking this pathology (14, 37). Therefore, it is relevant to
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study the physiological relevance of PKD-induced cMyBP-C
phosphorylation during contraction, which is the natural state
of living cardiomyocytes. In the present study, we analyzed the
consequences of increased contraction frequency on PKD-
mediated cMyBP-C phosphorylation and how this phosphory-
lation facilitates coping with increased contractile demands.
MATERIALS AND METHODS
Animals
Homozygous cardiac cMyBP-C-null (16) mice were generated in a
Black Swiss background as previously described by Carrier et al. (4).
Male Lewis rats (200–250 g) were obtained from Charles River. All
animal studies were approved by the Committee on Animal Experi-
mentation of Maastricht University and performed according to insti-
tutional guidelines and regulations.
Materials
Antibodies directed against PKD/PKC, phospho-PKD/PKC-
(Ser916), and phospho-Troponin-I (Ser22/23) were obtained from Cell
Signaling. The MYBPC3 antibody was obtained from Santa Cruz
Biotechnology. The phospho-cardiac myosin light chain-2 (MLC2)
(21) and the rat cMyBP-C-Ser315 antibody (36) were homemade. The
full-length active PKD was synthesized in the laboratory of Prof.
Johan Van Lint (42).
Oligomycin, staurosporine, calphostin-C, Gö-6983, protein kinase
inhibitor (PKI), and isoproterenol were from Sigma (St. Louis, MO).
Isolation and Treatment of Adult Rat Cardiomyocytes
Cardiomyocytes were isolated from male Lewis rats (200–250 g)
using a Langendorff perfusion system and a Krebs Henseleit bicar-
bonate medium equilibrated with a 95% O2-5% CO2 gas phase at
37°C as previously described (27). Cardiomyocytes were incubated
for 6 min at 37°C with continuous shaking and electrically stimulated
for 6 min using a commercially available Ionoptix stimulator (4 Hz,
40 V, pulse duration 5 ms).
Immunoprecipitation
Rat cardiomyocytes were pelleted and resuspended for 1 h in
ice-cold lysis buffer: 50 mmol/l Tris·HCl (pH  7.4), 150 mmol/l
NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
Complete protease inhibitor (Roche), and PhosSTOP phosphatase
inhibitor (Roche). Cells were pelleted by centrifugation for 10 min at
14,000 g, 4°C. Supernatant fractions (500 l) were incubated with the
PKD or MYBPC3 (K-16) antibody (5 g) overnight at 4°C on a
rotating wheel. Thereafter, 50 l of Protein G Sepharose bead sus-
pension (GE Healthcare) were added, and incubations were continued
for 1 h at 4°C. The beads were collected by pulse centrifugation and
washed. The final pellet was resuspended in 30 l 1 sample buffer
and heated to 95°C for 5 min. The beads were pelleted by centrifu-
gation at 12,000 g for 20 s, and the supernatant was used for Western
blot analysis.
Immunoblotting
Proteins were separated by using 4–12% SDS-PAGE gels and
transferred to nitrocellulose membranes for Western Blotting. The
membranes were probed with the relevant primary antibodies. The
protein bands were visualized using enhanced chemiluminescence,
and immunoblot intensities were analyzed by densitometry as de-
scribed previously (28).
Permeabilized Myocyte Preparations
Ventricular mouse myocytes were dissociated mechanically as
previously described (6). The heart was perfused retrogradely (1.6
ml/min) with a Ca2-free Hanks-HEPES buffered solution for 5 min
at room temperature then preskinned by perfusing with relaxing solution
containing 1% Triton X-100 and protease inhibitors (complete cocktail
tablets; Roche) (1 tablet was dissolved in 50 ml relaxing solution) for
10 min. Left ventricular strips (8 mm long, 2 mm width, 1 mm thick)
were dissected from the same heart, frozen in liquid nitrogen for
biochemistry, or further skinned for 10 min at 4°C in relaxing solution
containing 1% Triton X-100 for mechanical experiments. The strips
were then blended in fresh ice-cold relaxing solution at 6,098 g for
2–3 s (Polytron PT45–80 with a PTA 10TS shaft; KINEMATICA),
resulting in a suspension of small clumps of myocyte-sized prepara-
tions and cell fragments. The homogenized tissue was filtered and
centrifuged at 500 g for 1 min at 4°C. The pellet containing the
myocytes was skinned in 0.3% Triton X-100 solution for 6 min to
remove remaining membranes and then was extensively washed in
relaxing solution. To prevent degradation, all solutions contained
protease inhibitors (see above). Cells were kept on ice and used within
the day. Some cells were used immediately after cell isolation for
mechanical experiments; others were solubilized for immunoblotting.
For PKD stimulation, cells were preincubated for 30 min at room
temperature with 10 g of full-length active PKD per milliliter of
relaxing solution.
Solutions. Ca2-activating solutions were prepared by mixing re-
laxing (pCa 9.0) and maximal activating (pCa 4.5) stock solutions.
The relaxing and activating solutions contained (in mmol/l) 12 phos-
phocreatine, 30 imidazole, 1 free Mg2, 10 EGTA, 3.3 Na2ATP, and
0.3 dithiothreitol with pCa 9.0 (relaxing solution) and pCa 4.5 (max-
imal activating solution), pH 7.1.
Force measurements. The procedure of cell attachment has been
described previously (6). A skinned myocyte was attached to a
piezo-resistive strain gauge (AE801 sensor; Memscap, Crolle, France;
500 Hz unloaded resonant frequency, compliance of the strain gauge
0.03 m/N) and to a stepper motor-driven micromanipulator (MP-
285; Sutter Instrument), cardiomyocyte at 2.0 m sarcomeric length
(44). Contractions were induced by application of solutions containing
various pCa (from 6.2 to 4.5).
Statistics
Data are presented as means  SE. The paired Student’s t-test and
one-way ANOVA (for the mechanical experiments) was used. When
significant interactions were found, a Bonferroni post hoc test was
applied. A value of P  0.05 indicates a statistical significance.
RESULTS
Contraction Increases PKD Binding and Phosphorylation on
cMyBP-C
We previously demonstrated that contraction induced by
electric field stimulation (EFS) activates PKD in isolated rat
cardiomyocytes (28). Because cMyBP-C has been shown to be
one of the targets of PKD (1), we first investigated whether
phosphorylation of cMyBP-C is increased during contraction.
We measured phosphorylation of cMyBP-C-Ser315 in electric
field-stimulated rat cardiomyocytes, since this site has been
shown to be preferentially phosphorylated by the catalytic
subunit of PKD in quiescent mouse myocardium (1). Com-
pared with quiescent cardiomyocytes, EFS increased the phos-
phorylation of cMyBP-C-Ser315 (Fig. 1A). During EFS of rat
cardiomyocytes, PKD phopshorylates cMyBP-C-Ser315, and it
does this by directly interacting with cMyBP-C, as shown by
immunoprecipitation (Fig. 1B). Immunoprecipitation of PKD
showed an increased binding to cMyBP-C-Ser315 with EFS,
indicating that, during EFS, PKD phopsphorylates cMyBP-C-
Ser315 by directly interacting with cMyBP-C (Fig. 1B). Recip-
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rocally, after immunoprecipitation of cMyBP-C, PKD was
co-immunoprecipitated with cMyBP-C, and the level of coim-
munoprecipitated PKD was markedly higher in EFS-treated
cardiomyocytes than in quiescent cardiomyocytes (Fig. 1B,
second panel).
We then applied a pharmacological approach to inhibit activa-
tion of PKD in EFS-treated cardiomyocytes by pretreating the
cardiomyocytes with various PKC/PKD inhibitors (Fig. 2). We
used staurosporine as a general PKC/PKD inhibitor, calphos-
tin-C as an inhibitor of all diacylglycerol-activated PKC and
PKD isoforms, and finally Gö-6983, which blocks conven-
tional PKCs. The EFS-induced phosphorylation of cMyBP-C-
Ser315 was prevented by staurosporine or calphostin-C, but not
with Gö-6983. To further explore the PKC-dependent and
PKC-independent activation of PKD following EFS, cardio-
myocytes were treated with oligomycin, which has been shown
to activate only PKD and not the main cardiac PKC isoforms
(28). Similar to EFS, oligomycin treatment of cardiomyocytes
increased the phosphorylation of cMyBP-C-Ser315, which was
blocked by staurosporine or calphostin-C, but not with Gö-
6983. Altogether the results suggest that, during contraction,
cMyBP-C is a direct target of PKD.
cMyBP-C-Ser315 Phosphorylation by PKD is Contraction
Frequency Dependent
PKD-mediated cMyBP-C phosphorylation was deter-
mined at different EFS frequencies in isolated rat cardio-
myocytes. Compared with quiescent rat cardiomyocytes,
EFS at 1, 2, and 4 Hz increased PKD-Ser916 phosphorylation
by 1.7-, 2.7-, and 3.2-fold and cMyBP-C-Ser315 phosphor-
ylation by 3.1-, 4.4-, and 5.1-fold, respectively (Fig. 3). The
parallel upregulation in contraction-induced PKD and
cMyBP-C phosphorylation strongly supports the concept
that PKD-dependent phosphorylation is instrumental for the
cardiomyocyte to adjust to an increased contraction fre-
quency.
PKD-Dependent Phosphorylation of cMyBP-C Regulates
Contractility in Cardiomyocytes
The effect of PKD-mediated phosphorylation of cMyBP-C
on myofilament function was studied in permeabilized ventric-
ular cardiomyocytes derived from cMyBP-C-knockout (KO)
mice and wild-type (WT) littermates. Skinned cardiomyocytes
were incubated with full-length active PKD to mimic as close
as possible the in vivo conditions. The stimulation with PKD of
the WT skinned myocytes induced an increase in cMyBP-C-
Ser315 phosphorylation (4-fold), and to a lesser extent in TnI
phosphorylation (2-fold) and MLC2 phosphorylation (2-fold)
(Fig. 4A).
The physiological effect of cMyBP-C phosphorylation by PKD
and the relationship between Ca2-activated tension and internal
Ca2 concentrations (expressed as pCa  log[Ca2]) in per-
meabilized myocytes from WT and cMyBP-C KO mice were
determined. Experiments were performed at 2.0 m sarcomere
length (SL), which is the length close to the conditions of the
experiments in intact myocytes and also because a previous
publication showed that cMyBP-C affects myofilament Ca2
sensitivity at short SL and that stretch masks this effect at
longer lengths (6). In WT myocytes, PKD increased the abso-
lute maximal Ca2-activated tension of contraction (Tmax) and
submaximal active tension starting from pCa 5.875. These
effects of PKD on Tmax were abolished in cMyBP-C KO
myocytes, showing that cMyBP-C is involved in the PKD-
mediated increase in the tension of the muscle fiber during
contraction. This raised the question whether this increase in
force was due to an increase in myofilament Ca2 sensitiv-
ity. PKD induced a leftward shift of the relative tension-pCa
relationship curve and therefore increased in pCa50 in both
WT and KO myocytes (Fig. 4B), indicating that the PKD-
mediated effect on pCa50 was independent of cMyBP-C
(Fig. 4B). Other contractile parameters such as Hill coeffi-
cient and passive tension were not affected by PKD treat-
ment (data not shown).
To test whether the PKD-mediated effects on myofilament
function were dependent on prior PKA activation, cMyBP-C
KO and WT mice were pretreated for 3 days before death with
the nonselective -blocker propranolol, which neutralizes PKA
activity. In WT mice pretreated with -blocker, full-length
active PKD was able to phosphorylate cMyBP-C-Ser315 and
MLC-2 but not TnI (Fig. 4C). In WT and KO mice pretreated
with -blocker, Ca2 sensitivity was increased compared with
nontreated mice (5.63  0.02 to 5.78  0.04 and 5.66  0.02
to 5.83  0.05 in WT and KO, respectively), which is an
expected effect of the -blocker treatment. Also, a reduction in
phosphorylated TnI was observed. PKD did not alter either
pCa50 or Tmax (Fig. 4D), indicating that the effect of PKD on
pCa50 and Tmax is dependent on prior PKA activation. Because
the -blocker treatment neutralized the effect of PKD on Tmax,
but not on cMyBP-C-Ser315 phosphoryation, we tested whether
Fig. 1. Interaction between protein kinase D (PKD) and cardiac myosin-
binding protein C (cMyBP-C) upon increased contraction. Isolated rat cardio-
myocytes were electrical field stimulated (EFS) at 4 Hz for 6 min and were
compared with nonstimulated cardiomyocytes. A: cMyBP-C-Ser315 becomes
phosphorylated (p) during EFS. B: upon PKD immunoprecipitation (IP),
cMyBP-C-Ser315 and PKD were detected by immunoblotting (IB) (35). Upon
cMyBP-C IP, cMyBP-C and PKD were detected by immunoblotting (35).
Results shown are representative for three independent experiments.
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PKD was able to phosphorylate cMyBP-C-Ser295. Previously,
it was shown that cMyBP-C-Ser282 in mouse, which is equiv-
alent to cMyBP-C-Ser295 in rat (47), becomes phosphorylated
upon PKA activation (15). However, PKD is not able to
phosphorylate cMyBP-C-Ser295, neither in -blocker-treated
or in untreated mice (Fig. 5A). This is in agreement with an
earlier publications (1, 47), which showed that, in mouse
cardiomyocytes, PKD only phosphorylates Ser302 and not
Ser282 or Ser273 on cMyBP-C (which are equivalent to cMyBP-
C-Ser315, Ser295, and Ser273 in rat).
For better understanding of the role of PKA in the PKD-
mediated cMyBP-C phosphorylation, we finally tested whether
acute PKA activation is necessary for PKD to be able to
phosphorylate cMyBP-C. Isoproterenol (10 M), a classic
agonist, was used to activate PKA and increase the intracellular
concentration of cAMP in cardiomyocytes (29). Here we show
that isoproterenol was able to induce both cMyBP-C-Ser295
and cMyBP-C-Ser315 phosphorylation. However, oligomycin,
which activates PKD signaling (14), was only able to induce
cMyBP-C-Ser315 phosphorylation (Fig. 5B). Furthermore, spe-
cific blockade of PKA with the PKI did not prevent the
oligomycin-induced cMyBP-C-Ser315 phosphorylation (Fig.
5B), whereas it largely blocked the isoproterenol-induced
phosphorylation of both cMyBP-C-Ser315 and cMyBP-C-
Ser295 (Fig. 5B). Thus, PKD activation (using oligomycin or a
full-length PKD construct) results in phosphorylation of only
cMyBP-C-Ser315 and not cMyBP-C-Ser295, whereas isoproter-
enol stimulation results in phosphorylation of both cMyBP-C-
Ser315 and cMyBP-C-Ser295. Because isoproterenol is not able
to phosphorylate PKD-Ser916 (Fig. 5B), and PKI was not able
to inhibit oligomycin-stimulated cMyBP-C-Ser315 phosphory-
lation, we can conclude that PKA is not upstream of PKD but
rather acts via a separate pathway. Together, these data suggest
that prior PKA activation is necessary for PKD-mediated
cMyBp-C-Ser315 phosphorylation to affect myofilament func-
tion.
DISCUSSION
Phosphorylation of cMyBP-C is markedly decreased in
experimental models of cardiac pathology and in human heart
failure, and as such it has been considered to be an important
regulator of cardiac contractility (2, 14, 37). Understanding its
regulation and the mechanisms by which cMyBP-C phosphor-
ylation mediates cardiac contractile responses is critical in
developing its potential as therapeutic target. We therefore
investigated the PKD-mediated regulation of myofilament con-
traction through phosphorylation of cMyBP-C, and we show
that cMyBP-C is involved in PKD-mediated increase in myo-
filament activation, but not in the PKD-mediated Ca2 sensi-
tization of the myofilaments.
Fig. 2. Effects of protein kinase C/PKD inhibi-
tors on cMyBP-C phosphorylation in cardiomy-
ocytes. Isolated rat cardiomyocytes were prein-
cubated for 15 min at 37°C with or without
addition of 1 mol/l staurosporine (Stau), 2
mol/l calphostin-C (20), or 10 mol/L Gö-
6983. Subsequently, cardiomyocytes were elec-
tric field stimulated or treated with 5 mol/l
oligomycin. Samples were immunoblotted for
Ser315 phosphorylation of cMyBP-C and caveo-
lin 3 (Cav3) (loading control). The blots shown
are representative for three independent experi-
ments.
Fig. 3. PKD-Ser916 (A) and cMyBP-C-Ser315 (B) phosphorylation increases upon
increased contraction frequency. Isolated rat cardiomyocytes were electrically
stimulated at 1, 2, and 4 Hz for 6 min and were compared with quiescent cells.
Samples were probed against phospho-PKD-Ser916 and phospho-cMyBP-C-Ser315
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, loading control). Val-
ues are expressed as multiple of control. Results are representative of 3 indepen-
dent experiments.
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During Contraction, PKD Phosphorylates cMyBP-C-Ser315
in Rat Cardiomyocytes
This study is the first to show that, during contraction,
cMyBP-C is a direct physiological substrate of PKD. Previ-
ously, cMyBP-C has been described as a substrate of PKD in
trabeculae under noncontracting conditions (1). Our data show
that, during contraction, PKD is activated, which is character-
ized by its Ser916 phosphorylation. This activation leads to an
increased binding of PKD to cMyBP-C. In response to in-
creased cardiac contractile activity (evoked by EFS of the
cells), the Ser315 site of cMyBP-C becomes phosphorylated by
PKD. During increased contraction frequencies, phosphoryla-
tion of both PKD-Ser916 and cMyBP-C-Ser315 increases simi-
larly. This concomitant phosphorylation in combination with
direct physical interaction strongly suggests a functional rela-
tionship between the two proteins.
PKD-Directed cMyBP-C Phosphorylation Alters the Cardiac
Contractility
Several studies have shown that exercise increases Ca2
sensitivity of muscle tension and leads to a higher generated
force (11, 32, 44). In exercising rats, Tmax of the ventricular
papillary muscle at optimal length increased significantly (31).
Also, in porcine cardiac myofilaments, phosphorylation of
cMyBP-C was increased in response to endurance exercise
training (22). Here we report that phosphorylation of cMyBP-
Fig. 4. PKD increases myofilament Ca2 sensitivity and maximal tension of contraction. A: Western blot analysis of levels of p-MyBP-Ser315, p-troponin I (TnI),
and p-myosin light chain-2 (MLC2) in mouse myofilaments incubated for 30 min with full-length active PKD. The blots show that PKD is capable of
phosphorylation of all three proteins. Caveolin-3 is used as a loading control. B: the relationship between Ca2-activated tension and intracellular Ca2
concentrations was measured in isolated, permeabilized cardiomyocytes at 2.0 m sarcomere length. The relationship was fitted with a modified Hill equation,
and the pCa at which half of the maximal tension is developed (pCa50) was determined as an index of myofilament Ca2 sensitivity as described previously (5).
Incubation of wild-type (WT) cardiomyocytes with full-length active PKD increased myofilament Ca2 sensitivity, which is indicated by the shift toward the
left of the curve and the increase of pCa50. Also, incubation of WT cardiomyocytes with PKD increased maximal tension of contraction (Tmax), which is indicated
by the upward shift of the curve. In cMyBP-C knockout (KO) cardiomyocytes, incubation with full-length active PKD still increased pCa50, whereas PKD was
not able anymore to affect Tmax. C: -blocker treatment of WT mice did not interfere with PKD-induced cMyBP-C or MLC2 phosphorylation but prevented
PKD-mediated TnI phosphorylation. D: in both WT and cMyBP-C KO cardiomyocytes from mice, pretreated with -blockers, the PKD-mediated effects on
pCa50 and Tmax were abolished. Results are expressed as means  SE, n  12 cells/group. *P  0.05.
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C-Ser315, by application of an activated full-length PKD,
results in an increase in submaximal and maximal Ca2 acti-
vation. We showed that interaction of PKD with cMyBP-C
increased during contraction of cardiomyocytes. Furthermore,
during a rise in contraction frequency, phosphorylation of both
PKD and cMyBP-C was increased. Also, the relevance of
submaximal activation and Tmax increases with increasing
contraction frequency. Thus, the PKD-mediated effect on
cMyBP-C appears to become relevant during periods of high
contraction. The involvement of PKD in the force-frequency
relationship is supported by data in cardiac-specific PKD KO
mice that displayed normal contractility but were unable to
respond to stress (18).
In submaximal and maximal contraction, cMyBP-C seems
to be directly involved as a mediator in the PKD-driven force
development. On the other hand, the PKD-mediated change in
Ca2 sensitivity was independent of cMyBP-C, suggesting the
involvement of other regulatory proteins. This is in agreement
with a recent study in mouse trabeculae stimulated with the
catalytic subunit of PKD that showed that cTnI phosphoryla-
tion at Ser22/23 is responsible for PKD-mediated regulation of
myofilament Ca2 sensitivity but not for the PKD-mediated
acceleration of cross-bridge cycling kinetics (1). Recent studies
using transgenic animals have shown that cMyBP-C plays an
essential role in the PKA-mediated acceleration of cross-bridge
cycling kinetics (39 ,41) and is required for PKA-induced
decrease of myofilament Ca2 sensitivity (6, 7). The mecha-
nism by which PKD activation leads to an increased pCa50 may
imply phosphorylation of other contractile proteins, such as
MLC2. Experiments in rabbit septal muscle preparations re-
vealed a significant frequency-dependent increase in MLC2
phosphorylation, which is known to increase myofilament
Fig. 5. cMyBP-C-Ser315 phosphorylation is in-
dependent of acute PKA activation or inhibi-
tion. A: Western blot analysis of phosphoryla-
tion of MyBP-Ser295 in mouse myofilaments
incubated for 30 min with full-length active
PKD from untreated or -blocker-pretreated
mice. B: phosphorylation of cMyBP-C-Ser295,
cMyBP-C-Ser315, and PKD-Ser916 was mea-
sured in rat cardiomyocytes after isoproterenol
(ISO) or oligomycin stimulation in the absence
or presence of 10 mol/l protein kinase inhibi-
tor (PKI). The data shown are representative for
three independent experiments. *P  0.05 vs.
basal conditions.
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Ca2 sensitivity (19, 40). Also, increased MLC2 phosphory-
lation and heart rate are attributed to different levels of tread-
mill exercise or -adrenergic stimulation and inhibition (17).
These data are in line with the concept that increased contrac-
tion frequency results in activation of PKD and subsequent
Ca2 sensitivity, independent of cMyBP-C. Nevertheless,
Cuello and coworkers (9) showed a PKD-reduced myofilament
Ca2 sensitivity in mice pretreated with propranolol, which
prevents PKA activation (9). This study also reported that
PKD-mediated TnI phosphorylation decreased Ca2 sensitiv-
ity. Their data are contradictory with our results. However,
there are several methodological differences that could account
for the discrepancies. For example, we used a full-length PKD,
whereas the other study was performed with only the catalytic
domain. It seems likely that full-length PKD and catalytic
domain PKD have different binding characteristics and that
these differences may affect the interaction between PKD and
target proteins and/or the extent of phosphorylation. Also, the
SL (2.0 vs. 2.2 m) and the condition of PKD stimulation
(separate vs. same batch of nonstimulated and PKD-stimulated
cells) were different. Finally, the other investigators used only
propranolol-pretreated animals.
In the present study, in propranolol-pretreated mice, PKD
was still able to phosphorylate cMyBP-C-Ser315 but lost its
effects on maximal activation and myofilament Ca2 sensitiv-
ity in both WT and KO mice. Using a transgenic mouse model
in which particular sites of TnI cannot be phosphorylated by
PKA, Bardswell and coworkers (1) showed that PKD lost its
ability to change myofilament Ca2 sensitivity. This has also
been described in human cardiomyocytes derived from donor
and failing hearts in which the phoshorylation background of
sarcomeric proteins affected PKA-dependent phosphorylation
of TnI and myofilament Ca2 sensitivity (23). Together with
our results, this suggests that the effect of PKD on myofilament
properties is dependent on prior PKA-dependent phosphoryla-
tion of regulatory contractile proteins. Upon activation, PKA is
able to desensitize the muscle fiber for Ca2-mediated force
development and to increase cross-bridge cycle kinetics (1, 24,
30, 33). In our study, acute PKA activation does lead to direct
phosphorylation of both cMyBP-C-Ser315 and cMyBP-Ser295,
whereas PKD activation only leads to phosphorylation of
cMyBP-Ser315 and not cMyBP-C-Ser295. Also, PKA inhibition
by PKI did not affect phosphorylation of PKD-Ser916, which
indicates that PKA does not function uptream of PKD. Most
likely, a former PKA-mediated cMyBP-C phosphorylation of
Ser295 may be necessary for the PKD-mediated effect on
myofilament Tmax. Thus, PKD-mediated cMyBP-C phosphor-
ylation alone appears to be insufficient to increase myofilament
Tmax and may require preceding phosphorylation particular
residues. Furthermore, application of the -adrenergic blocker
propranolol led to a marked increase in pCa50, which could not
be further increased by PKD. Although propranolol pretreat-
ment did not interfere with the PKD-mediated MLC2 phos-
phorylation, it did prevent PKD-induced TnI phosphorylation.
Previously, it has been shown that isoproterenol increases
phosphorylation of both TnI and MLC2. Also, it has been
shown that MLC2 phosphorylation increases myofilament
Ca2 sensitivity (19, 33). Thus, PKD-stimulated increase in
Ca2 sensitivity is at least in part mediated by phosphorylation
of TnI and MLC-2.
Because phosphorylation of both PKD-Ser916 and cMyBP-
C-Ser315 increases during increased contraction frequencies,
and the PKD-mediated effect on myofilament Tmax is inhibited
by inhibiting the PKA pathway (using -adrenergic blockers),
our results suggest that combined PKA and PKD activation
becomes necessary during increased contraction or exercise to
coordinate the contraction mechanics. Interestingly, there is a
basal -adrenergic tone that is increased during various con-
ditions of cardiac stress, such as exercise (38) and heart failure
(5). Given that, during increased contraction, PKD is also
involved in enhanced glucose uptake (12, 28), it can be
suggested that PKD activation helps the cardiomyocytes to
cope with an increased contraction frequency by 1) providing
the cells with energy-rich substrate through an increase in
glucose uptake and 2) phosphorylating cMyBP-C to increase
Tmax. In this way, PKA is necessary for basal myofilament
function, whereas PKD becomes important during increased
contraction frequencies. Thus, PKD might provide a way for
mutual adjustment of cardiac energetics and contractile me-
chanics during increased contraction frequencies (Fig. 6).
Fig. 6. Schematic representation of the combined PKA and PKD action during
increased contraction or exercise, needed to coordinate the contraction me-
chanics. A: a basal -adrenergic tone leads to the activation of PKA and
regulates contraction by phosphorylation of sarcomeric proteins, such as
cMyBP-C and TnI. B: stimuli, like electric field stimulation, will increase the
contraction frequency of the cardiomyocytes. This increase will lead to
phosphorylation of PKD and cMyBP-C-Ser315. To cope with increased con-
tractile demands, PKD facilitates contraction by increasing the Ca2 sensitivity
of contraction (pCa50) and by inducing cMyBP-C-Ser315 phosphorylation,
which leads to an increase in Tmax. However, prior PKA activation of
cMyBP-C-Ser295 is necessary for PKD-mediated cMyBP-C-Ser315 phosphor-
ylation, so the combined action of both kinases is needed to come to a full
deployment of contractile force.
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In conclusion, an increase in contraction frequency induced
by EFS leads to the phosphorylation of both PKD and
cMyBP-C in isolated cardiomyocytes. To facilitate coping with
increased contractile demands, PKD increases the myofilament
Ca2 sensitivity and induces cMyBP-C phosphorylation,
which leads to an increase in maximal tension of contraction.
In addition, PKD increase glucose uptake for energy produc-
tion. Thus, PKD harmonizes contractile force with Ca2 sen-
sitivity and with energy supply and is therefore essential for the
cardiomyocyte to properly respond to an increased contraction
frequency, which happens during periods of increased contrac-
tile activity when both the contractile performance and energy
demand of the cardiomyocytes are highest.
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